Insulin antibodies in patients with type 2 diabetes mellitus

To assess the prevalence of insulin antibodies (IA-A) and their binding capacity (c%IA-A) in Type-2 diabetic patients and relation of IA-A/c%IA-A to duration of diabetes, type of therapy, kind/dosage of administered insulin, glycaemic control and to appearance of hypoglycaemic episodes. 196 hospital...

Full description

Saved in:
Bibliographic Details
Published inVnitřní lékar̆stvĭ Vol. 44; no. 10; p. 577
Main Authors Martinka, E, Straková, J, Mokán, M
Format Journal Article
LanguageSlovak
Published Czech Republic 01.10.1998
Subjects
Aged
Blood Glucose - analysis
C-Peptide - blood
Diabetes Mellitus, Type 2 - immunology
Diabetes Mellitus, Type 2 - therapy
Humans
Insulin Antibodies - blood
Online AccessGet more information

Cover

More Information
Summary:To assess the prevalence of insulin antibodies (IA-A) and their binding capacity (c%IA-A) in Type-2 diabetic patients and relation of IA-A/c%IA-A to duration of diabetes, type of therapy, kind/dosage of administered insulin, glycaemic control and to appearance of hypoglycaemic episodes. 196 hospitalised patients with type-2 diabetes mellitus (negative for antiGAD-Ab). Assessed parameters: age, duration of diabetes mellitus, duration of insulin-therapy, BMI, glycaemic profile, IRI, C-peptide, IA-A and antiGAD-Ab (Cis bio international, distr. fy Solupharm). Prevalence of IA-A and their c%IA-A were related to treatment with insulin. c%IA-A correlated significantly with fasting plasma glucose and IRI concentrations. c%IA-A did not correlate with insulin dosages, C-peptide, BMI, nor with age. Prevalence of IA-A and their c%IA-A in patients with Type-2 diabetes affects levels of total plasma insulin, insulin kinetic and consequently the quality of glycaemic compensation. Prevalence of IA-A is related to duration of insulin therapy, but independent on dosage of administered insulin.
ISSN:0042-773X